Proteasome inhibitor: anti-tumor activities and clinical applicationZHOU Yong-ming, GUO Wei, HUANG Shi-ang1813-1818
Advances in research of nitric oxide-donor drugs as anticancer agentsWANG Lan, ZHAO Guang-rong, WANG Wei-dong, ZHANG Guang-ming1818-1823,1836
Outlines of phase transformation considerations in solid oral formulationsWANG Hong, CHEN Yi-hong, LIU Gui-yang1824-1827
Establishment and application of a high throughput microtubule-targeted screening assaySUN Wan, LI Min, WEI Shao-yin, WU Jun, XU Bo, CUI Jing-rong1828-1831
Framework-reengineering and its application in humanized antibody fSM03LIANG Rui-an, YANG Lei, CHEN Jun-xin, CHEN Han-wen, LI Zheng-dong, HUANG Pei-fen, CHEUNG Wing-tai1832-1836
Absorptions of Eb versus its HP-β-CD inclusion complex in rat gastrointestinal tractCUI Han-ming, WU Feng-lan1837-1841
Preparation and pharmacokinetics of paclitaxel nanometric liposomes in ratsWANG Qing-song, SHA Xian-yi, HAN Li-mei, GUO Jie, FANG Xiao-ling1842-1845
Anti-tumor activity of realgar nanoparticles and the distribution of arsenic (As) in tissues of tumor-transplanted miceXU Ling-yun, ZENG Fan-dian, YE Han-qing, YANG Xiang-liang, XU Hui-bi1845-1849